Poster Sessions

Print this page

  Personalized Programme
The Personalized Programme enables you to compile an individual program with events and contributions of your interest. Therefore, it can be used very well to plan your actual congress visit at an early point of time. Please log on with your username and password to use the Personalized Programme.
» Login
» Create account
» Help
   
 

Thursday, 14 September 2017

next day »
     
No. P-01 - Poster Session
Time: 13.30-14.30
Room: Event Area, Ground Floor
Session title: Diagnosis and epidemiology
  Frauke Schultze-Lutter, Bern, Switzerland Chairperson
     
No. P-02 - Poster Session
Time: 13.30-14.30
Room: Event Area, Ground Floor
Session title: Drug and alternative treatment 1
  Sonia Dollfus, Caen, France Chairperson
     
001 Effects of risperidone and olanzapine on indices of weight and fatty component of body composition of patients with schizophrenia  
  Elena Kornetova, Tomsk, Russia Speaker
003 Extrapyramidal side effects in elderly schizophrenic patients  
  Mihai Mutica, Bucharest, Romania Speaker
004 Association between serum glutamate and BDNF levels and response of schizophrenia patients to clozapine treatment  
  Michal Taler, Petach-Tikva, Israel Speaker
005 Cardiotoxicity associated with clozapine; a potent hypothesis of immunomodulation by clozapine: a case report  
  Emmanouil Rizos, Athens - Haidari, Greece Speaker
006 A randomised, double-blind, placebo-controlled study to assess cardiac effects of single-dose BI 409306 in healthy male volunteers  
  Claudia Völk, Ingelheim am Rhein, Germany Speaker
007 Prevention of relapse in schizophrenia: a phase II study evaluating efficacy, safety, and tolerability of oral BI 409306  
  Michael Sand, Ridgefield, USA Speaker
008 The influence of 3 weeks of antipsychotic treatment on cell adhesion molecules in drug naive patients with schizophrenia spectrum disorder  
  Farivar Fathian, Bergen, Norway Speaker
009 First episode of schizophrenia under antipsychotic treatment is followed by recovery of monoamine oxidase activity but not the degree of endogenous intoxication  
  Marat Uzbekov, Moscow, Russia Speaker
010 Psychopathology and differentiated psychopharmacological treatment strategy in subtypes of 22q11.2 deletion syndrome  
  Willem M. A. Verhoeven, Venray, Netherlands Speaker
011 New 1,5-benzodiazepin-2-ones with anticonvulsant and tranquilizer activity  
  Vitalii Palchykov, Dnipro, Ukraine Speaker
012 Pitfalls of managing schizophrenia  
  Mohammed Farik Jabir, Singapore, Singapore Speaker
     
No. P-03 - Poster Session
Time: 13.30-14.30
Room: Event Area, Ground Floor
Session title: Outcome and stigma
  Armida Mucci, Naples, Italy Chairperson
     
001 Predictors of remission in late-life schizophrenia: a 5-year follow-up study in a Dutch psychiatric catchment area  
  Sjors Lange, Amsterdam, Netherlands Speaker
002 Predictors of remission in the acute treatment of first-episode schizophrenia involuntarily hospitalized and treated with an algorithm-based pharmacotherapy: secondary analysis of an observational study  
  Bunta Yoshimura, Miyakojima, Japan Speaker
003 The time-course of negative symptoms and their relationships with social functioning and quality of life of first episode schizophrenia patients: a prospective 11 - 15 year follow - study  
  Katarzyna Golêbiewska, Poznañ, Poland Speaker
004 A description of physical health outcomes in a first episode psychosis xohort over 20 years  
  Donal O´Keeffe, Dublin, Ireland Speaker
005 The financial crisis in Greece and the impact on psychiatric patients  
  Markella Fiste, Chaidari Athens, Greece Speaker
006 Burden of disease for caregivers of individuals with schizophrenia  
  Mihail Cristian Pirlog, Bucharest, Romania Speaker
007 Psychosocial functioning of families and anti-relapse behaviour in schizophrenia  
  Elena Gutkevich, Tomsk, Russia Speaker
008 Stigma experiences in first-episode patients with schizophrenia: do they erode self-esteem in the long-term?  
  Harald Zäske, Düsseldorf, Germany Speaker
009 Effects of psychological skills training on family stigma in schizophrenia  
  Farshid Shamsaei, Hamedan, Islamic Republic of Iran Speaker
010 Impact and differences of perceived course of illness on desire for social distance towards people suffering from schizophrenia or depression in Hanoi, Vietnam  
  Lara Kim Martensen, Berlin, Germany Speaker
011 An ongoing trial for recovery-oriented and co-productive reform of academic schizophrenia research society: a challenge of the Japanese Society of Schizophrenia Research  
  Masato Fukuda, Maebashi, Gunma, Japan Speaker
     
No. P-04 - Poster Session
Time: 13.30-14.30
Room: Event Area, Ground Floor
Session title: Neuropsychology
  Daniel Freeman, Oxford, United Kingdom Chairperson